SCHEMBL7609803

SCHEMBL7609803

Brc1cccc(-c2nccs2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 1/20 0.60
CYP2A6 P11509 1/20 0.53
LOXL2 Q9Y4K0 1/20 0.49
RAB9A P51151 2/20 0.45
ALDH1A1 P00352 1/20 0.45
MAPT P10636 1/20 0.45
HPGD P15428 1/20 0.45
HK1 P19367 1/20 0.45
HKDC1 Q2TB90 1/20 0.45
CYP19A1 P11511 1/20 0.44
TLR7 Q9NYK1 1/20 0.44
PTGDR2 Q9Y5Y4 1/20 0.43
ABL1 P00519 1/20 0.42
BCR P11274 1/20 0.42
KAT6A Q92794 1/20 0.42
ADK P55263 1/20 0.41
FFAR1 O14842 1/20 0.41
ADRB2 P07550 1/20 0.41
DCTPP1 Q9H773 1/20 0.41
BIRC5 O15392 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15805858 0.86 PDPK1 (0.72) PDPK1CYP2A6LOXL2RAB9APTGDR2
SCHEMBL16159287 0.82 PDPK1 (0.67) PDPK1CYP2A6LOXL2RAB9APTGDR2
SCHEMBL4425765 0.79 PDPK1 (0.74) PDPK1CYP2A6LOXL2RAB9APTGDR2
SCHEMBL468088 0.78 PDPK1 (0.60) PDPK1CYP2A6LOXL2RAB9AALDH1A1
SCHEMBL173979 0.78 PDPK1 (0.60) PDPK1CYP2A6LOXL2ALDH1A1MAPT
SCHEMBL31609722 0.78 PDPK1 (0.60) PDPK1CYP2A6LOXL2RAB9ACYP19A1
SCHEMBL13025 0.78 PDPK1 (0.60) PDPK1CYP2A6LOXL2ALDH1A1HPGD
SCHEMBL11153399 0.78 PDPK1 (0.60) PDPK1CYP2A6LOXL2RAB9APTGDR2
SCHEMBL20550702 0.78 PDPK1 (0.60) PDPK1CYP2A6LOXL2CYP19A1PTGDR2
SCHEMBL30668080 0.78 PDPK1 (0.60) PDPK1CYP2A6LOXL2RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260103471-A1 CYCLIC UREA THIAZOLYL COMPOUNDS FOR TREATMENT OF HSV ASSEMBLY BIOSCIENCES INC (US) 2026-04-16 US disclosed
US-20250376478-A1 CYCLIC UREA THIAZOLYL COMPOUNDS FOR TREATMENT OF HSV ASSEMBLY BIOSCIENCES INC (US) 2025-12-11 US disclosed
EP-4581029-A1 CYCLIC UREA THIAZOLYL COMPOUNDS FOR TREATMENT OF HSV Assembly Biosciences, Inc. (US) 2025-07-09 EP disclosed
CN-119546602-A Pyrrolidone derivatives as inhibitors of nfkb-induced kinase 詹森药业有限公司 2025-02-28 CN disclosed
WO-2024049760-A1 CYCLIC UREA THIAZOLYL COMPOUNDS FOR TREATMENT OF HSV ASSEMBLY BIOSCIENCES, INC. (US) 2024-03-07 WO disclosed
US-20230322691-A1 ORGANIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT CANON KABUSHIKI KAISHA (JP) 2023-10-12 US disclosed
US-20230322691-A1 ORGANIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT CANON KABUSHIKI KAISHA (JP) 2023-10-12 US disclosed
US-10710978-B2 STK4 inhibitors for treatment of hematologic malignancies DANA-FARBER CANCER INSTITUTE, INC. (US) 2020-07-14 US disclosed
US-20180111916-A1 STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES FONDAZIONE CENTRO SAN RAFFAELE (IT) 2018-04-26 US disclosed
WO-2016161145-A1 STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES DANA-FARBER CANCER INSTITUTE, INC. (US) 2016-10-06 WO disclosed
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 US disclosed
US-20140308317-A1 Polymeric Compounds And Methods Of Making And Using The Same CELLCEUTIX CORPORATION (US) 2014-10-16 US disclosed
US-20140308317-A1 Polymeric Compounds And Methods Of Making And Using The Same CELLCEUTIX CORPORATION (US) 2014-10-16 US disclosed
WO-2014093225-A2 POLYCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME CELLCEUTIX CORPORATION (US) 2014-06-19 WO disclosed
CN-103313970-A Novel bicyclic compound or salt thereof TAIHO PHARMACEUTICAL CO LTD 2013-09-18 CN disclosed
CN-101189233-A Substituted diazabicycloalkane derivatives as ligands for the alpha 7 nicotinic acetylcholine receptor ABBOTT LAB (US) 2008-05-28 CN disclosed
US-6423471-B1 TITANOCENE, ETHYLENICALLY UNSATURATED MONOMER, AND PIGMENT; PHOTOPOLYMERIZABLE FUJI PHOTO FILM CO., LTD. (JP) 2002-07-23 US disclosed
EP-0385496-A2 Color light-sensitive material FUJI PHOTO FILM CO., LTD. (JP) 1990-09-05 EP disclosed
EP-0297804-A2 Silver halide photographic light-sensitive material KONICA CORPORATION (JP) 1989-01-04 EP disclosed
EP-0105425-B1 SILVER HALIDE PHOTOGRAPHIC LIGHT SENSITIVE MATERIAL FUJI PHOTO FILM CO., LTD. (JP) 1987-05-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260103471-A1 CYCLIC UREA THIAZOLYL COMPOUNDS FOR TREATMENT OF HSV TK1, UNG, SMCHD1 PDPK1 2756/4885CYP2A6 4355/4885LOXL2 3289/4885
US-20230322691-A1 ORGANIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT CCNT1, CCNE2, SCO2 PDPK1 3978/4885CYP2A6 658/4885LOXL2 65/4885
US-20180111916-A1 STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES STK4, STK3, STK11 PDPK1 56/4885CYP2A6 4266/4885LOXL2 2678/4885
US-10710978-B2 STK4 inhibitors for treatment of hematologic malignancies STK4, STK3, STK11 PDPK1 56/4885CYP2A6 4266/4885LOXL2 2678/4885
US-20250376478-A1 CYCLIC UREA THIAZOLYL COMPOUNDS FOR TREATMENT OF HSV TYMP, TK1, TREH PDPK1 362/4885CYP2A6 4378/4885LOXL2 4442/4885
US-20140308317-A1 Polymeric Compounds And Methods Of Making And Using The Same ALG1, CD44, MUC1 PDPK1 2134/4885CYP2A6 3440/4885LOXL2 1063/4885
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE PPP2CA, PPP4C, PPP3CB PDPK1 495/4885CYP2A6 3927/4885LOXL2 900/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.